OMS302, our second lead product candidate, is being developed for use during ophthalmological procedures, including cataract and other lens replacement surgery. OMS302 is a proprietary combination of an anti-inflammatory agent and an agent that causes pupil dilation (mydriasis) each with well-known safety and pharmacologic profiles. FDA-approved drugs containing each of these active agents have been used in ophthalmological clinical practice for more than 15 years, and both agents are contained in generic, FDA-approved drugs.

OMS302 is added to standard irrigation solution used in cataract and other lens replacement surgery, and is delivered directly into the anterior chamber of the eye to maintain mydriasis, to prevent surgically induced pupil constriction (miosis), and to reduce postoperative pain and irritation. Mydriasis is an essential prerequisite for these procedures and, if not maintained throughout the surgical procedure or if miosis occurs, risk of damaging structures within the eye increases as does the operating time required to perform the procedure.

In a Phase 2b clinical trial of OMS302 in patients undergoing cataract surgery, OMS302 demonstrated clinically meaningful and statistically significant benefits in both prespecified co-primary endpoints, maintenance of intraoperative mydriasis (pupil dilation) and reduction of pain in the early postoperative period. OMS302 also reduced the frequency of complaints of moderate and severe pain. OMS302 is currently in a Phase 3 clinical program.